Aptevo Therapeutics(APVO)

Search documents
Aptevo Therapeutics(APVO) - 2024 Q3 - Quarterly Results
2024-11-07 13:15
Aptevo Therapeutics 3Q 2024 Financial Results and Business Update [Business Highlights](index=1&type=section&id=Business%20Highlights) Aptevo Therapeutics achieved significant clinical milestones in Q3 2024, advancing key trials and successfully raising $5.75 million - Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," for frontline Acute Myeloid Leukemia (AML) patients, combining it with standard of care venetox and azacitidine[1](index=1&type=chunk)[2](index=2&type=chunk) - Presented positive interim data from the ALG.APV-527 Phase 1 trial at the ESMO Congress, with **9 out of 15 (60%) efficacy evaluable patients achieving a best overall response of stable disease (SD)**[2](index=2&type=chunk) - The ALG.APV-527 trial demonstrated a well-tolerated safety profile and confirmed biological activity through biomarker analyses[3](index=3&type=chunk) - Raised a total of **$5.75 million** through two financing deals during the third quarter[1](index=1&type=chunk)[3](index=3&type=chunk) [3Q 2024 Summary Financial Results](index=2&type=section&id=3Q%20Summary%20Financial%20Results) Aptevo reported a Q3 2024 net loss of $5.1 million, reduced from the prior year, with $7.8 million cash and lower operating expenses Q3 2024 Financial Highlights (vs. Q3 2023) | Financial Metric | Q3 2024 | Q3 2023 | Change | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | $7.8 million | N/A | - | | Research & Development Expenses | $3.1 million | $3.9 million | -$0.8 million | | General & Administrative Expenses | $2.1 million | $2.7 million | -$0.6 million | | Net Loss | $5.1 million | $6.3 million | -$1.2 million | | Net Loss Per Share | $0.48 | $22.16 | - | - The decrease in R&D expenses was primarily due to lower spending on preclinical projects and employee costs[4](index=4&type=chunk) - The decrease in G&A expenses was mainly attributed to lower employee and consulting costs[5](index=5&type=chunk) Financial Statements [Condensed Consolidated Balance Sheets](index=3&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of September 30, 2024, Aptevo's total assets were $15.1 million, with liabilities at $10.7 million and equity at $4.4 million Balance Sheet Summary (in thousands) | Account | Sep 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $7,753 | $16,904 | | Total current assets | $10,012 | $19,066 | | **Total assets** | **$15,146** | **$24,842** | | **Liabilities & Equity** | | | | Total current liabilities | $5,882 | $7,224 | | **Total liabilities** | **$10,726** | **$12,621** | | **Total stockholders' equity** | **$4,420** | **$12,221** | [Condensed Consolidated Statements of Operations](index=4&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Aptevo reported a Q3 2024 net loss of $5.1 million ($0.48 per share) and a nine-month net loss of $17.8 million Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended Sep 30, 2024 | Three Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $(3,103) | $(3,887) | $(10,498) | $(13,516) | | General and administrative | $(2,110) | $(2,674) | $(7,722) | $(8,978) | | Loss from operations | $(5,213) | $(6,561) | $(18,220) | $(22,494) | | Net loss from continuing operations | $(5,101) | $(6,334) | $(17,818) | $(12,454) | | Net loss | $(5,101) | $(6,334) | $(17,818) | $(11,508) | | Basic and diluted net loss per share | $(0.48) | $(22.16) | $(5.01) | $(56.22) | Company Information and Forward-Looking Statements [About Aptevo Therapeutics Inc.](index=5&type=section&id=About%20Aptevo%20Therapeutics%20Inc.) Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel immuno-oncology therapies for cancer treatment - Aptevo is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies to treat cancer[13](index=13&type=chunk) [Safe Harbor Statement](index=5&type=section&id=Safe%20Harbor%20Statement) This section outlines forward-looking statements, cautioning that actual results may differ due to clinical, regulatory, and macroeconomic risks - The press release includes forward-looking statements concerning the efficacy, safety, and potential of its therapeutic candidates, progress of clinical programs, and financial position[14](index=14&type=chunk) - Warns that actual results may differ materially due to risks such as adverse clinical trial outcomes, regulatory hurdles, competitive products, and macroeconomic factors like inflation and geopolitical risks[15](index=15&type=chunk)[17](index=17&type=chunk) - Investors are directed to the company's SEC filings, including the Annual Report on Form 10-K, for a more comprehensive discussion of risks and uncertainties[17](index=17&type=chunk)
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's What You Should Know
ZACKS· 2024-08-15 17:06
Aptevo Therapeutics Inc. (APVO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...
Aptevo Therapeutics(APVO) - 2024 Q2 - Quarterly Report
2024-08-08 12:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | --- | |------------------------------------------|-----------------------------------|------------------ ...
Aptevo Therapeutics(APVO) - 2024 Q2 - Quarterly Results
2024-08-08 12:15
Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE SEATTLE, WA – August 8, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, ...
Aptevo Therapeutics(APVO) - 2024 Q1 - Quarterly Report
2024-05-08 12:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | --- | |------------------------------------------|-----------------------------------|----------------- ...
Aptevo Therapeutics(APVO) - 2024 Q1 - Quarterly Results
2024-05-08 12:15
Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 1Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new adverse events since the transition to the higher dose level APVO436 Phase 1b/2 dose optimization trial initiation of ...
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
Zacks Investment Research· 2024-04-16 17:51
Aptevo Therapeutics (APVO) is a clinical-stage pharmaceutical company focused on developing novel therapies targeting cancer indications.In the past week, the company’s stock lost 79.0%. This downside came after management came out with a secondary issue of 3.4 million shares of its common stock to the public at an issue price of $1.35 per share, amounting to $4.6 million in gross proceeds. The issue was closed on Apr 15.Per the public offer’s terms, each common stock will be accompanied by two warrants. Ea ...
Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today?
InvestorPlace· 2024-04-11 12:15
Aptevo Therapeutics (NASDAQ:APVO) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares.That public offering has Aptevo Therapeutics selling 3.4 million shares of APVO stock at a price of $1.35 each. The shares also come with warrants to purchase another 6.8 million shares of the company’s stock.Aptevo Therapeutics notes that the exercise price for the warrants in this offer is also $1.35 per share. The warrants are exercisable immediately and ex ...
Aptevo Therapeutics(APVO) - 2023 Q4 - Annual Results
2024-03-04 16:00
Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA – March 5, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune ...
Aptevo Therapeutics(APVO) - 2023 Q4 - Annual Report
2024-03-04 16:00
th | --- | --- | --- | |------------------------------------------------------|------------------|-----------------------------------------------------------------------| | Title of Each Class | Trading Symbol | Name of Exchange on Which Registered | | Common Stock, $0.001 par value per share | APVO | The Nasdaq Stock Market LLC (The Nasdaq Capital Market) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...